| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/100-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Tyrosine kinase-type cell surface receptor HER3 |
| Entrez GeneID | 2065; |
| WB Predicted band size | 185kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Peptide sequence around phosphorylation site of tyrosine 1328 (P-D-Y(p)-W-H) derived from Human Her3/ErbB3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于Her3/ErbB3 (phospho-Tyr1328)抗体的示例参考文献(内容为模拟示例，实际文献需通过学术数据库查询)：
---
1. **文献名称**：*"HER3 phosphorylation at Tyr1328 mediates resistance to EGFR-targeted therapy in lung cancer"*
**作者**：Smith A et al.
**摘要**：本研究揭示了Her3在EGFR抑制剂耐药中的关键作用，通过Western blot和免疫组化使用phospho-Tyr1328抗体，证实Tyr1328磷酸化激活下游PI3K/AKT通路，促进肿瘤细胞存活。
2. **文献名称**：*"Structural basis of ErbB3 receptor tyrosine kinase ligand binding and activation"*
**作者**：Jones B et al.
**摘要**：通过晶体结构分析和磷酸化检测，阐明Her3受体Tyr1328位点的磷酸化对其与配体heregulin结合及异源二聚化(如与HER2)的关键影响，实验中利用特异性phospho-Tyr1328抗体验证激活状态。
3. **文献名称**：*"Dual targeting of HER2 and HER3 phosphorylation in breast cancer models"*
**作者**：Lee C et al.
**摘要**：研究开发了针对HER2/HER3双靶点抑制剂，使用phospho-Tyr1328抗体证明药物可显著抑制Her3磷酸化，阻断肿瘤生长并增强化疗敏感性。
4. **文献名称**：*"Phosphoproteomic profiling identifies HER3-Tyr1328 as a biomarker of poor prognosis in colorectal cancer"*
**作者**：Wang D et al.
**摘要**：通过大规模磷酸化蛋白质组学分析，发现Her3 Tyr1328磷酸化水平与结直肠癌转移相关，采用该抗体进行组织微阵列验证，提示其作为预后标志物的潜力。
---
**建议**：实际文献可通过PubMed、Google Scholar等平台，以关键词 **"HER3 Tyr1328 phosphorylation antibody"** 或 **"ErbB3 phospho-Tyr1328"** 检索，并筛选涉及信号机制、癌症治疗或抗体开发的研究。
The Her3/ErbB3 (phospho-Tyr1328) antibody is a specialized tool used to study the activation status of the HER3 receptor, a member of the ErbB tyrosine kinase family. HER3 lacks intrinsic kinase activity and relies on heterodimerization with other ErbB receptors, particularly HER2. for downstream signaling. Phosphorylation at Tyr1328. located in the kinase domain's activation loop, is a critical event triggered by ligand binding (e.g., neuregulins) or cross-activation. This modification induces conformational changes, enabling HER3 to recruit adaptor proteins like PI3K via its six docking sites, thereby activating oncogenic pathways such as PI3K/AKT and MAPK.
The phospho-specific antibody detects HER3 only when phosphorylated at Tyr1328. making it essential for investigating receptor activation dynamics in cancer research. Overexpression or hyperactivation of HER3 is linked to resistance to EGFR/HER2-targeted therapies, emphasizing its clinical relevance. Researchers employ this antibody in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess HER3 activation in cell lines, tumor tissues, or preclinical models. Validated antibodies ensure specificity through knockout/knockdown controls or peptide competition assays. Its application aids in understanding HER3's role in tumor progression, therapeutic resistance mechanisms, and the development of combination therapies targeting ErbB signaling networks.
×
